Global Edible Vaccine Market Size By Type (Inactivated Vaccines), By Application (Livestock, Medical Care), By Geographic Scope And Forecast

Edible Vaccine Market Size And Forecast

Edible Vaccine Market size was valued at USD 7.01 Billion in 2021 and is projected to reach USD 11.36 Billion by 2030, growing at a CAGR of 6.18% from 2023 to 2030.

The increasing significance of vaccines and antibodies, as well as the rising awareness of the need for health intervention in both animals and humans, are all factors that are contributing to the enormous rise of the Edible Vaccine Market. Additionally, the ongoing research into the development of an edible vaccine is imposing a favorable perspective on the growth of the market. This is imposing a positive outlook on the growth of the market. The Global Edible Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Edible Vaccine Market Definition

Oral vaccinations made from transgenic plants are widely referred to as Edible Vaccines. It entails selecting the desired genes and then allowing transformed plants to create encoded proteins. These vaccinations provide convenience, storage, and delivery while being cost-effective. It also has superior genetic and heat stability and requires less cold-chain maintenance. It is frequently used in livestock, medical care, and other areas. In many ways, edible vaccines differ from regular vaccines and overcome many of their limitations. Traditional vaccines can be prohibitively expensive or difficult to make and develop in some regions. On the other hand, edible vaccinations are simple to manufacture, purify, sterilize, and distribute. The cost of producing vaccinations is greatly reduced because they do not require expensive production equipment, merely rich soil.

Furthermore, unlike traditional vaccines, edible vaccines do not require sterilized production facilities or the biosafety regulations required to produce specific pathogenic agents, which are costly to develop and maintain. They are also less expensive and easier to store because they do not require stringent refrigerated storage. The need for cold chain storage causes a slew of problems in developing countries. The seeds of an edible vaccine plant can also be easily dehydrated and kept for low-cost and speedy distribution, making them readily available in times of need.

Edible vaccinations do not require auxiliary components to induce an immune response like standard immunizations. The possibility of adverse consequences, such as allergic reactions, is one of the primary worries regarding conventional vaccines. Due to the fact that edible vaccines do not contain any pathogens or hazardous substances and instead only contain therapeutic proteins, the possibility of adverse effects and allergic reactions is drastically decreased.

Global Edible Vaccine Market Overview

The increasing significance of vaccines and antibodies, as well as the rising awareness of the need for health intervention in both animals and humans, are all factors that are contributing to the enormous rise of the Edible Vaccine Market. Additionally, the ongoing research into the development of an edible vaccine is imposing a favorable perspective on the growth of the market. This is imposing a positive outlook on the growth of the market. Due to the increased understanding of the importance of healthcare, there has been a significant shift in emphasis toward immunization, and a number of government organizations are currently working toward accomplishing this objective through various projects. For instance, monies for the acquisition of vaccinations are provided by the Immunize Australia Program, which is run by the government of Australia.

In addition, the program is responsible for the administration of the National Immunization Program (NIP) Schedule. This schedule includes vaccinations against 16 different diseases, such as measles, diphtheria, and whooping cough (pertussis), in addition to more recently developed vaccines, such as the HPV vaccine and the meningococcal ACWY vaccine. From the moment they are born, all Australians are required to follow this routine. The expansion of the market is being driven by such reasons. Measles, diphtheria, pertussis, tetanus, oral polio, and BCG are mature vaccinations. High fixed costs and a steep learning curve make new vaccines more expensive since R&D and production facility investments must be recouped and optimal manufacturing processes must be perfected to reduce variable production costs.

New vaccines using recombinant DNA or polysaccharide-protein conjugation may not be suitable for large-scale manufacture. These vaccines may never achieve the same low pricing as the six EPI vaccines. However, Therapeutic vaccinations treat rather than prevent. Improved immunology has allowed the development of therapeutic vaccinations for cancer, allergies, physiological problems, and infectious diseases. Patients with such conditions seek alternate therapy. Scientists have developed self-antigen-targeted vaccinations for hypertension, dyslipidemia, Alzheimer’s, cancer, and inflammatory illnesses.

Global Edible Vaccine Market Segmentation Analysis

The Global Edible Vaccine Market is Segmented on the basis of Type, Application, And Geography.

Edible Vaccine Market, By Type

• Inactivated Vaccines
• Others

Based on Type, the market is segmented into Inactivated Vaccines and others. In the year 2020, the section of the worldwide Edible Vaccine Market that was comprised of conjugate vaccines held the most market share of any other form of vaccine, with the exception of COVID-19 vaccines. Conjugate vaccines are created by connecting antigens or toxoids from a microbe in order to train an individual’s immune system to identify the polysaccharides that are produced by bacteria. Because of this relationship, the immune systems of newborns and young children are better able to react to the polysaccharides and develop immunity to the bacterium. These advantages, which are provided by the vaccinations, are helping to drive the market share.

Edible Vaccine Market, By Application

• Livestock
• Medical Care
• Others

Based on Application, the market is segmented into Livestock, Medical Care, and Others. The segment that comprised the largest proportion of the Edible Vaccine Market was the pediatric consumer sector (excluding COVID-19 vaccines). This growth can be attributed to the fact that vaccinations tend to be more effective in children because their immune systems respond better to vaccines and help them gain lifelong immunity against specific diseases. Additionally, this growth can be attributed to the fact that children are more likely to receive vaccinations than adults. Children are also at a higher risk for contracting a number of infectious diseases, including tuberculosis, measles, hepatitis, and cholera, all of which underline the need for efficient pediatric immunization.

Edible Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of The World

Based on Geography, the Global Edible Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world in 2021. During the period covered by this estimate, it is anticipated that the market for vaccinations in the Asia Pacific will record the greatest CAGR overall (including COVID-19 vaccines) and overall (excluding COVID-19 vaccines). To achieve cost savings, an increasing number of pharmaceutical and vaccine companies are contracting out significant portions of their research and development work, mostly to clinical and contract research and manufacturing groups. This is one of the most important factors contributing to the expansion of the Edible Vaccine Market in the Asia Pacific region.

Key Players

The “Global Edible Vaccine Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline, Sanofi S.A., Merck & Co., Inc., Ceva, Santa Cruz Animal Health, and Merial. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Pfizer acquired an Emergency Use Authorization (EUA) from the US FDA in October 2021 for the Pfizer-BioNTech COVID-19 Vaccine for children aged 5 to 11.
• The Pfizer-BioNTech COVID-19 vaccine COMIRNATY obtained final US FDA approval in August 2021 for those aged 16 and up.
• GSK got US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in July 2021 to prevent shingles (herpes zoster) in individuals 18 years and older with immunodeficiency or immunosuppression induced by disease or therapy.
• Merck will offer VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate, and Hepatitis B Vaccine) in June 2021.

Report Scope